Preliminary results for the year ended 30 June 2025

STRONG PERFORMANCE AND SUBSTANTIAL STRATEGIC PROGRESS ACHIEVED

Continued good second half momentum drove strong full year financial performance

• PIC – Continued strong trading across the Americas and Asia in the second half; adjusted operating profit including joint ventures increased 16%2 for the year
• ABS – Value Acceleration Programme (“VAP”) initiatives delivering significant adjusted operating profit and cash flow improvement; substantial improvement in adjusted operating profit to £19.5m (FY24: £14.0m)
• Group adjusted operating profit including joint ventures increased 19% to £93.1m in actual currency driven by broad-based growth in PIC and VAP actions benefitting ABS
• Adjusted profit before tax (“PBT”) increased 24% to £74.3 in actual currency (38% increase in constant currency) including the net £3.7m FDA milestone receipt from the Group’s Chinese partner Beijing Capital Agribusiness
• Statutory PBT of £28.5m (FY24: £5.5m) was predominantly impacted by a £13.3m decrease in the non-cash IAS41 fair value valuation of biological assets and net exceptional expenses of £11.4m (FY24: £24.6m)
• Adjusted earnings per share increased 25% and final dividend maintained at 21.7p per share with 2.6x1 adjusted earnings cover, in line with our policy
• Very strong adjusted cash generated by operations of £106.2m (FY24: £55.1m) and conversion1 of 114% (FY24: 71%) resulting in record free cash inflow1 of £40.9m (FY24: £3.2m outflow), inclusive of £24.2m (FY24: £17.9m) of expected exceptional cash outflows
• Net debt1 of £228.2m down £20.5m from prior year, and a year-end net debt to adjusted EBITDA ratio of 1.5x1 (30 June 2024: 2.0x1), calculated as per our financing facility, driven by stronger free cash flow and lower USD debt on translation to sterling

Substantial strategic progress achieved

• Porcine: Continued growth ex-China with total royalty revenue increasing 5% in constant currency, new royalty customer momentum continued in China with 12 new royalty customer wins in the year and 25 new royalty customers now signed over the last two years
• PRRS⁵ Resistant Pig (“PRP”): Landmark U.S. Food and Drug Administration (“FDA”) approval of the PRP gene edit for use in the U.S. food supply chain achieved in April 2025; good continuing progress with regulators in Canada, Mexico, Japan and other international jurisdictions
• Bovine: VAP Phase 2 successfully completed, delivering annualised adjusted operating profit benefit of £10m with £8m realised in FY25; VAP Phase 3 initiatives identified and being actioned with an annualised adjusted operating profit benefit of approximately £9m, with an estimated £6m expected to be realised in FY26; De Novo joint venture acquisition in October 2024 delivering improvements in proprietary genetic product development

Accelerated Chinese porcine joint venture formation announced separately today

• Genus and its Chinese strategic partner, Beijing Capital Agribusiness (“BCA”), have signed agreements to accelerate the formation of a Chinese joint venture 51% owned by BCA and 49% owned by Genus
• Joint venture formation strengthens PIC China’s local positioning, accelerates the long-term growth opportunity and provides the best possible route to achieving PRP commercialisation in China
• Accelerated value crystallisation with retained future economic rights; Genus will receive a gross cash payment of US$160m upon completion (estimated US$140m, net of tax and transaction costs), an accelerated timeline for the US$7.5m of remaining milestone payments under the original agreements and intellectual property royalties from the joint venture on PRP sales in China that are consistent with the original agreements

FY26 outlook in-line with market expectations

• Market conditions are stable albeit management remains vigilant of potential geopolitical-driven market volatility
• Broadly neutral currency impact expected in FY26 if current exchange rates continue throughout the fiscal year
• The Board expects significant growth in Group adjusted profit before tax in constant currency, in line with current market expectations⁴

Commenting on the performance and outlook, Jorgen Kokke, Chief Executive, said:
“Genus achieved a strong performance in FY25 as we executed our strategic priorities. PIC’s growth was broad- based and the business won significant new royalty customers in China. ABS profitability was substantially improved, primarily through VAP initiatives. In addition, we secured the landmark U.S. FDA approval for our PRP gene edit and this tremendous achievement is testament to our teams and partners who have been working on the PRP programme for over a decade. We look forward to FY26 with increasing confidence and will continue to focus on executing our strategic priorities.”

Enquiries:

You can see PDF with full financial results here

Additional resources: Financial Results Webcast and Investor Presentation

About Genus

Genus’s core commercial proposition is helping farmers rear healthier animals that produce more high-quality animal protein with fewer resources. Genus advances genetic improvement through genomic selection and biotechnology. The Group sells its products and services to livestock farmers and food producers predominantly in the dairy, beef and pork food production sectors.

Genus's worldwide sales are made in over 85 countries under the trademarks 'ABS' (dairy and beef cattle) and 'PIC' (pigs) and comprise semen, embryos and breeding animals with superior genetics to those animals currently in farms. Genus's customers' animals produce offspring with greater production efficiency and quality, and our customers use them to supply the global dairy and meat supply chains.

Genus’s competitive edge comes from the ownership and control of proprietary lines of breeding animals, the biotechnology used to improve them and its global supply chain, technical service and sales and distribution network. The PRP is a market leading innovation in gene editing, which Genus is looking to commercialise in the porcine industry once regulatory approval is gained in certain markets.

Headquartered in Basingstoke, United Kingdom, Genus companies operate in over 24 countries on six continents, with research laboratories located in Madison, Wisconsin, USA.

_{¹ Adjusted results are the Alternative Performance Measures (‘APMs’) used by the Board to monitor underlying performance at a Group and operating segment level, which are applied consistently throughout. These APMs should be considered in addition to, and not as a substitute for or as superior to statutory measures. For more information on APMs, see APM Glossary
² Constant currency percentage movements are calculated by restating the results for the year ended 30 June 2025 at the average exchange rates applied to adjusted operating profit for the year ended 30 June 2024
³ n/a = not applicable
⁴ The company compiled consensus range for FY26 adjusted profit before tax is £76.1m to £86.0m with an average of £79.0m. This is based upon 9 analyst estimates
⁵ Porcine Reproductive and Respiratory Syndrome}